Caribou Biosciences vs Innate Pharma SA
Caribou Biosciences and Innate Pharma SA are similar in size: $11.2m and $10.2m of revenue in their latest fiscal years. Caribou Biosciences grew faster (11.7% against -53.2%). Innate Pharma SA kept more of each dollar of sales as profit: a net margin of -546.1% against -1327.4%.
| Latest fiscal year | Caribou BiosciencesCRBU, 2025 | Innate Pharma SAIPHA, 2025 |
|---|---|---|
| Revenue | $11.2m | $10.2m |
| Revenue growth | 11.7% | -53.2% |
| Net income | −$148m | −$55.6m |
| Operating margin | -1329.4% | -599.8% |
| Net margin | -1327.4% | -546.1% |
| Return on equity | -79.0% | — |
| Free cash flow | −$112m | −$59.8m |
| Cash | $12.4m | $33.0m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $46.6m | $125m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 0 buys, 0 sales |